Durvalumab for limited stage small-cell lung cancer after
1 therapy

Durvalumab is in clinical development for the treatment of adults with limited stage small-cell
lung cancer (LS-SCLC) whose cancer has not worsened since receiving concurrent chemoradiation
therapy (cCRT). SCLC is a form of lung cancer characterised by the appearance of the tumour cells
under a microscope. Limited stage SCLC occurs when the cancer is only seen on one side of the
chest and is small in size. Symptoms may include cough, difficulty breathing chest pain,
hoarseness, fatigue and weight loss. LS-SCLC treatment, which includes cCRT and preventative
radiotherapy of the brain, is an area of unmet need and the standard of care has not changed in
decades.